EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-Metaanalyse

Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials

Hong Sun iD, Fengjiao Bu, Ling Li, Xiuwen Zhang, Xiu Xin, Jingchao Yan, Taomin Huang

Annals of Pharmacotherapy · 2024

DOI: 10.1177/10600280231188171 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Hong Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Different clinical trials for recurrent or metastatic nasopharyngeal carcinoma have studied different combinations of immuno-oncology in first-line treatment, but the optimal choice has not been determined.

Objective

To systematically examine and compare the efficacy and safety of different immune checkpoint inhibitors (ICIs) combined with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.

Methods

Several electronic databases were systematically searched up to February 2023. Articles meeting the inclusion criteria were included.

Results

Three RCTs were eligible in the study. Compared with placebo plus gemcitabine-cisplatin (GP), toripalimab plus GP (HR = 0.59, 95% CI: 0.37-0.95) was significantly associated with a better OS. Tislelizumab plus GP generated best progression-free survival (PFS) benefit (HR = 0.50, 95% CI: 0.37-0.67), greatest improvement in 1-year PFS rate (RR = 3.00, 95% CI: 1.84-5.22), and objective response rate (ORR) (RR = 1.26, 95% CI: 1.04-1.53) over the placebo plus GP. Furthermore, tislelizumab plus GP appeared to be safer than toripalimab plus GP and camrelizumab plus GP in terms of adverse events (AEs)-grade ≥3, treatment-related AEs (TRAEs)-grade ≥3, serious AEs (SAEs), treatment-related SAEs (TRSAEs), and AEs leading to discontinuation of treatment. Conclusion and Relevance In recurrent or metastatic nasopharyngeal carcinoma, programmed death 1 (PD-1) inhibitors plus GP as first-line treatment have better survival outcomes than placebo plus GP with comparable toxicity. Toripalimab plus GP shows the best OS benefit over placebo plus GP, while tislelizumab plus GP generates the best PFS, 1-year PFS rate, ORR, and safety. Tislelizumab plus GP could be the best choice among the ICIs combined with chemotherapy regimens as first-line treatment in recurrent or metastatic nasopharyngeal carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsNasopharyngeal NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsNasopharyngeal CarcinomaRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

PD-1 inhibitorefficacyimmune checkpoint inhibitornasopharyngeal carcinomanetwork meta-analysissafety

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Hong Sun

Zitieren

APA

Sun, H., Bu, F., Li, L., Zhang, X., Xin, X., Yan, J., & Huang, T. (2024). Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231188171

Vancouver

Sun H, Bu F, Li L, Zhang X, Xin X, Yan J, et al. Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231188171

BibTeX
@article{Sun2024,
  author = {Sun, Hong and Bu, Fengjiao and Li, Ling and Zhang, Xiuwen and Xin, Xiu and Yan, Jingchao and Huang, Taomin},
  title = {Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials},
  journal = {Annals of Pharmacotherapy},
  year = {2024},
  doi = {10.1177/10600280231188171}
}
Kostenlos starten →